Lido Advisors
LGND icon

Lido Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Lido Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$796K Sell
2,517
-240
-9% -$56.6K ﹤0.01% 1217
2026
Q1 		$550K Buy
2,757
+525
+24% +$104K ﹤0.01% 1249
2025
Q4 		$401K Buy
2,232
+31
+1% +$5.96K ﹤0.01% 1400
2025
Q3 		$390K Buy
2,201
+42
+2% +$6.24K ﹤0.01% 1346
2025
Q2 		$245K Buy
+2,159
New +$231K ﹤0.01% 1424

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lido Advisors's LGND Position: Q2 2026 in Review

Lido Advisors reduced its Ligand Pharmaceuticals (LGND) stake by 8.7% in Q2 2026, selling an estimated $56.6K and leaving 2,517 shares worth $796K. The position accounts for ﹤0.01% of the portfolio, ranked #1217.

Lido Advisors first reported a position in LGND in Q2 2025 and has held it in 5 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Lido Advisors held 2,517 shares of Ligand Pharmaceuticals worth $796K as of Q2 2026.
  • Lido Advisors sold 240 Ligand Pharmaceuticals shares in Q2 2026, an estimated $56.6K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Lido Advisors's portfolio in Q2 2026, its #1217 holding.
  • Lido Advisors first reported a position in Ligand Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.